Insulin glulisine
Discontinued
The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
1 product record on the Australian Register of Therapeutic Goods, listed in full below. The TGA last updated this information on 28 October 2025. Not medical advice.
The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.
This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.
Insulin glulisine is subsidised on the PBS. The active ingredient is on the current Pharmaceutical Benefits Scheme, so it is a medicine dispensed under subsidy across Australia rather than one supplied through a narrower route. That is a fact about how widely it is used, not a rating of how serious this shortage is — the TGA's own impact rating above is the only severity statement on this page, and this does not change it.
A PBS listing is recorded against the active ingredient, while a shortage is usually reported against particular brands, strengths or pack sizes. So a subsidised alternative brand of the same ingredient may still be available even where a shortage is open. Your pharmacist can tell you what is in stock and can discuss substitutions with your prescriber.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Products affected
APIDRA insulin glulisine (rbe) 100IU/mL 10 mL injection vial
Injection, solution · ARTG 99145
- Status
- Discontinued The supplier has told the TGA it is permanently stopping supply of this product in Australia. This is not a temporary shortage. Other brands or strengths of the same medicine may still be available, and your doctor or pharmacist can advise on what to do next.
- Supply
- Reduction in supply until supply is exhausted The supplier reports reduced stock, which will run out and not be replaced.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 1 June 2026
- Expected to be resolved
- The TGA does not publish an end date for this record (it records "Unknown"). Voxsanity does not estimate one.
- TGA last updated
- 28 October 2025
What the TGA says is being done
Alternative presentations are available.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
Where this comes from
Source: Medicine Shortage Reports Database, Therapeutic Goods Administration (TGA), © Commonwealth of Australia, reproduced with permission. The TGA does not endorse Voxsanity, and nothing here is presented as a TGA view. Shortage information is free for everyone on this site, with no account and no subscription.
To read the TGA's own entry for Insulin glulisine, open the TGA Medicine Shortage Reports Database and type Insulin glulisine into its filter box. The TGA's register has no direct link to an individual medicine, so this is the closest link that exists. General information about medicine shortages is on the TGA's medicine shortages page.
Voxsanity last read the register on 18 August 2026.
Not medical advice. Voxsanity republishes public government health data in plain English. Speak to your pharmacist or doctor about your own medicines. Do not stop or change how you take a medicine because of anything on this page.